Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC30H29F3N6O |
InChIKeyXAXJKDYUXBSJJT-UHFFFAOYSA-N |
CAS Registry2566525-18-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Philadelphia chromosome positive chronic myelogenous leukemia | Preclinical | KR | 20 Jul 2023 |